Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Vyas JM, Feys S, Mansour MK, Wauters J, van de Veerdonk FL. The Changing Paradigm in Infectious Diseases-Host-Directed Medicine: Implications for the Next Generation of ID Physicians. J Infect Dis. 2026 Feb 18; 233(2):230-234.
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 Feb 10; 390:114581.
-
He SQ, Huang Y, Zhao ZY, Wen SQ, Lv SH, Wang L, Bei WX, Xiang YQ, Liu GY. Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study. Br J Cancer. 2026 Feb; 134(4):598-607.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
-
Krieg AM. New insights into the role of IFN-a/? and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity. J Immunother Cancer. 2025 Sep 18; 13(9).
-
Murata K, Minowa T, Tsukahara T, Yoshida T, Minami A, Nakatsugawa M, Mizue Y, Murai A, Tokita S, Sasaki K, Uhara H, Kubo T, Kanaseki T, Torigoe T, Hirohashi Y. An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer. Oncoimmunology. 2025 Dec; 14(1):2528110.
-
Brazel D, Kazakova V, Fay M, Bollin K, Mittal K, Reynolds KL, Tsang M. Connecting the Dots: Practical Strategies for Academic and Community Oncology Synergy to Advance Multidisciplinary Management in Immunotherapy Toxicity Care. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473080.
-
Skelly DA, Graham JP, Cheng M, Furuta M, Walter A, Stoklasek TA, Yang H, Stearns TM, Poirion O, Zhang JG, Grassmann JDS, Luo D, Flynn WF, Courtois ET, Chang CH, Serreze DV, Menghi F, Reinholdt LG, Liu ET. Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. Cell Rep. 2025 May 27; 44(5):115698.